Providers reported Alzheimer’s treatment gains with Zunveyl in long-term care, but the BEACON study cannot prove cause and ...
Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...
Namzaric (donepezil and memantine), also known as MDX-8704, ADS-8704, and Arimenda, is an approved therapy for moderate to severe Alzheimer’s disease. Allergan markets the treatment in the U.S. and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results